Ki67-no evidence for its use in node-positive breast cancer

被引：63

作者：

Andre, Fabrice ^{[1
]}

Arnedos, Monica ^{[1
]}

Goubar, Aicha ^{[2
]}

Ghouadni, Amal ^{[1
]}

Delaloge, Suzette ^{[1
]}

机构：

[1] Inst Gustave Roussy, Dept Med Oncol, F-94800 Villejuif, France

[2] Inst Gustave Roussy, INSERM Unit UMR981, F-94800 Villejuif, France

来源：

NATURE REVIEWS CLINICAL ONCOLOGY | 2015年 / 12卷 / 05期

关键词：

ESTROGEN-RECEPTOR; GENE-EXPRESSION; DISTANT RECURRENCE; INTERNATIONAL KI67; PROGNOSTIC VALUE; PREDICTIVE-VALUE; LABELING INDEX; CHEMOTHERAPY; WOMEN; KI-67;

D O I：

10.1038/nrclinonc.2015.46

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The expression of Ki67 in breast cancer has been associated with the luminal B phenotype, a high risk of relapse, and likelihood of good response to neoadjuvant chemotherapy. Several guidelines propose assays to determine Ki67 expression levels to select which patients with early stage breast cancer and 1-3 positive axillary nodes should not receive adjuvant chemotherapy. We discuss why oncologists should not rely on the use of this biomarker for patients with early stage breast cancer and only 1-3 positive axillary nodes. First, Ki67 staining lacks analytical validity. Second, the performance of the biomarker for prognostic purposes is poor, with no compelling evidence to indicate that patients with oestrogen receptor (ER)-positive disease, low Ki67 expression and 1-3 positive axillary nodes have a very low risk of disease relapse. Finally, no robust evidence indicates that Ki67 staining predicts the efficacy of adjuvant chemotherapy. Overall, evidence does not support withholding adjuvant chemotherapy in patients with ER-positive, Ki67-low breast cancer and 1-3 positive nodes without risk in daily practice.

引用

页码：296 / 301

页数：6

共 35 条

[1] Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials [J].

Albain, K. ;

Anderson, S. ;

Arriagada, R. ;

Barlow, W. ;

Bergh, J. ;

Bliss, J. ;

Buyse, M. ;

Cameron, D. ;

Carrasco, E. ;

Clarke, M. ;

Correa, C. ;

Coates, A. ;

Collins, R. ;

Costantino, J. ;

Cutter, D. ;

Cuzick, J. ;

Darby, S. ;

Davidson, N. ;

Davies, C. ;

Davies, K. ;

Delmestri, A. ;

Di Leo, A. ;

Dowsett, M. ;

Elphinstone, P. ;

Evans, V. ;

Ewertz, M. ;

Gelber, R. ;

Gettins, L. ;

Geyer, C. ;

Goldhirsch, A. ;

Godwin, J. ;

Gray, R. ;

Gregory, C. ;

Hayes, D. ;

Hill, C. ;

Ingle, J. ;

Jakesz, R. ;

James, S. ;

Kaufmann, M. ;

Kerr, A. ;

MacKinnon, E. ;

McGale, P. ;

McHugh, T. ;

Norton, L. ;

Ohashi, Y. ;

Paik, S. ;

Pan, H. C. ;

Perez, E. ;

Peto, R. ;

Piccart, M. .

LANCET, 2012, 379 (9814) :432-444

[2] Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial [J].

Albain, Kathy S. ;

Barlow, William E. ;

Shak, Steven ;

Hortobagyi, Gabriel N. ;

Livingston, Robert B. ;

Yeh, I-Tien ;

Ravdin, Peter ;

Bugarini, Roberto ;

Boehner, Frederick L. ;

Davidson, Nancy E. ;

Sledge, George W. ;

Winer, Eric P. ;

Hudis, Clifford ;

Ingle, James N. ;

Perez, Edith A. ;

Pritchard, Kathleen I. ;

Shepherd, Lois ;

Gralow, Julie R. ;

Yoshizawa, Carl ;

Allred, D. Craig ;

Osborne, C. Kent ;

Hayes, Daniel F. .

LANCET ONCOLOGY, 2010, 11 (01) :55-65

[3] Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601) [J].

Bartlett, John M. S. ;

Munro, Alison F. ;

Dunn, Janet A. ;

McConkey, Christopher ;

Jordan, Sarah ;

Twelves, Chris J. ;

Cameron, David A. ;

Thomas, Jeremy ;

Campbell, Fiona M. ;

Rea, Daniel W. ;

Provenzano, Elena ;

Caldas, Carlos ;

Pharaoh, Paul ;

Hiller, Louise ;

Earl, Helena ;

Poole, Christopher J. .

LANCET ONCOLOGY, 2010, 11 (03) :266-274

[4] Recommendations from the EGAPP Working Group: can tumor gene expression in patients with breast cancer? [J].

Berg, Alfred O. ;

Grp, E. G. A. P. P. Working ;

Armstrong, Katrina ;

Botkin, Jeffrey ;

Calonge, Ned ;

Haddow, James ;

Hayes, Maxine ;

Kaye, Celia ;

Phillips, Kathryn A. ;

Piper, Margaret ;

Richards, Carolyn Sue ;

Scott, Joan A. ;

Strickland, Ora L. ;

Teutsch, Steven .

GENETICS IN MEDICINE, 2009, 11 (01) :66-73

[5] Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer [J].

Cheang, Maggie C. U. ;

Chia, Stephen K. ;

Voduc, David ;

Gao, Dongxia ;

Leung, Samuel ;

Snider, Jacqueline ;

Watson, Mark ;

Davies, Sherri ;

Bernard, Philip S. ;

Parker, Joel S. ;

Perou, Charles M. ;

Ellis, Matthew J. ;

Nielsen, Torsten O. .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2009, 101 (10) :736-750

[6] Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis [J].

Cortazar, Patricia ;

Zhang, Lijun ;

Untch, Michael ;

Mehta, Keyur ;

Costantino, Joseph P. ;

Wolmark, Norman ;

Bonnefoi, Herve ;

Cameron, David ;

Gianni, Luca ;

Valagussa, Pinuccia ;

Swain, Sandra M. ;

Prowell, Tatiana ;

Loibl, Sibylle ;

Wickerham, D. Lawrence ;

Bogaerts, Jan ;

Baselga, Jose ;

Perou, Charles ;

Blumenthal, Gideon ;

Blohmer, Jens ;

Mamounas, Eleftherios P. ;

Bergh, Jonas ;

Semiglazov, Vladimir ;

Justice, Robert ;

Eidtmann, Holger ;

Paik, Soonmyung ;

Piccart, Martine ;

Sridhara, Rajeshwari ;

Fasching, Peter A. ;

Slaets, Leen ;

Tang, Shenghui ;

Gerber, Bernd ;

Geyer, Charles E., Jr. ;

Pazdur, Richard ;

Ditsch, Nina ;

Rastogi, Priya ;

Eiermann, Wolfgang ;

von Minckwitz, Gunter .

LANCET, 2014, 384 (9938) :164-172

[7] Prognostic Value of a Combined Estrogen Receptor, Progesterone Receptor, Ki-67, and Human Epidermal Growth Factor Receptor 2 Immunohistochemical Score and Comparison With the Genomic Health Recurrence Score in Early Breast Cancer [J].

Cuzick, Jack ;

Dowsett, Mitch ;

Pineda, Silvia ;

Wale, Christopher ;

Salter, Janine ;

Quinn, Emma ;

Zabaglo, Lila ;

Mallon, Elizabeth ;

Green, Andrew R. ;

Ellis, Ian O. ;

Howell, Anthony ;

Buzdar, Aman U. ;

Forbes, John F. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (32) :4273-4278

[8] Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients [J].

de Azambuja, E. ;

Cardoso, F. ;

de Castro, G., Jr. ;

Colozza, M. ;

Mano, M. S. ;

Durbecq, V. ;

Sotiriou, C. ;

Larsimont, D. ;

Piccart-Gebhart, M. J. ;

Paesmans, M. .

BRITISH JOURNAL OF CANCER, 2007, 96 (10) :1504-1513

[9] Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study [J].

Dieci, M. V. ;

Criscitiello, C. ;

Goubar, A. ;

Viale, G. ;

Conte, P. ;

Guarneri, V. ;

Ficarra, G. ;

Mathieu, M. C. ;

Delaloge, S. ;

Curigliano, G. ;

Andre, F. .

ANNALS OF ONCOLOGY, 2014, 25 (03) :611-618

[10] Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group [J].

Dowsett, Mitch ;

Nielsen, Torsten O. ;

A'Hern, Roger ;

Bartlett, John ;

Coombes, R. Charles ;

Cuzick, Jack ;

Ellis, Matthew ;

Henry, N. Lynn ;

Hugh, Judith C. ;

Lively, Tracy ;

McShane, Lisa ;

Paik, Soon ;

Penault-Llorca, Frederique ;

Prudkin, Ljudmila ;

Regan, Meredith ;

Salter, Janine ;

Sotiriou, Christos ;

Smith, Ian E. ;

Viale, Giuseppe ;

Zujewski, Jo Anne ;

Hayes, Daniel F. .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2011, 103 (22) :1656-1664

← 1 2 3 4 →